What You Can Learn From Ocumension Therapeutics' (HKG:1477) P/S
When you see that almost half of the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios (or "P/S") below 1.4x, Ocumension Therapeutics (HKG:1477) looks to be giving off
歐康維視生物-B:二零二三年年報
Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug
Ocumension Therapeutics' (HKG:1477) new drug for treating postoperative inflammation successfully achieved the expected results in a phase III clinical trial, according to a Monday filing with the Hon
Okanvision Bio-B (01477.HK): Phase III clinical trial of OT-502 in China reached the main end
Gelonghui, April 15 | Okanvision Bio-B (01477.HK) announced that OT-502 (DEXYCU, dexamethasone implant), a new drug for treating post-operative inflammatory indications, has successfully reached the expected main efficacy endpoint of its phase III clinical trial. That is, on day 8, the proportion of subjects with anterior atrial atrial cell clearance (ACC grade 0) in the treatment group with dexamethasone implants was significantly higher than in the placebo group, proving that this product is safe and effective in controlling inflammation after cataract surgery. The company expects to submit an OT-502 new drug application to the Drug Evaluation Center of the China National Drug Administration in the near future. O
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
Ocumension Therapeutics (HKG:1477) said its new drug completed clinical phase III and will soon apply for a new drug registration, according to a Monday filing on the Hong Kong bourse. The drug, OT-70
Okanvision Bio-B (01477.HK): OT-702 phase III clinical trial completed in China
Gelonghui, April 8 | Okanvision Bio-B (01477.HK) announced that the phase III clinical trial of OT-702 (abercip intraocular injection solution, EYLEA biosimilar) has been successfully completed in China. OT-702 was jointly developed by the Group and its partner Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech”) (the company's shares are listed on the Hong Kong Stock Exchange Limited (stock code: 6955)). The phase III clinical study of OT-702 was carried out in cooperation between the two parties. The application for the new drug will be reviewed by the China Drug Administration in the near future
Ocumension Therapeutics' Loss for 2023 Narrows; Shares Down 4%
Ocumension Therapeutics (HKG:1477) booked a loss of 379.8 million yuan for the year ended Dec. 31, 2023, compared with a loss of 402.6 million yuan in the year-ago period, according to a filing with t
Okanvision Bio-B (01477.HK) annual revenue increased by 55.0% to 246 million yuan
Gelonghui, March 21 | Okanvision Bio-B (01477.HK) announced that for the year ended December 31, 2023, the company's revenue increased by 55.0% to RMB 246.4 million, mainly due to a sharp increase in revenue from sales of ophthalmic products and pharmaceutical product promotion services. For the year ended 31 December 2023, the company's loss was RMB 379.8 million, down 5.7% from RMB 402.6 million for the year ended 31 December 2022, mainly due to the increase in gross profit of RMB 41.4 million and R&D compared with last year
OCUMENSION-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints
Ocumension Therapeutics' (HKG:1477) phase 2 clinical trial for its OT-202 treatment for dry eye achieved primary clinical endpoints, according to a Thursday filing with the Hong Kong bourse. During th
OT-202, the first novel drug of its kind developed in-house by Okanvision Bio-B (01477) to treat dry eye, has reached the main clinical end of phase II clinical trials
Okanvision Bio-B (01477) announced OT, the first novel drug of its kind developed by the company to treat dry eye syndrome...
Companies Like Ocumension Therapeutics (HKG:1477) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the
Changes in Hong Kong stocks | Okanvision Bio-B (01477) is now up more than 7% Sinqi Eye Medication Atropine Eye Drops Approved Clinical Trials of Listed Companies' Products Previously Approved
Okanvision Bio-B (01477) is now up more than 7%. As of press release, it is up 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
Guojin Securities: The first domestic eye drops to slow myopia in children have been approved for sale and are expected to be released quickly with a first-mover advantage
On March 11, according to the official website of the State Drug Administration, Sinqi Pharmaceutical (300573.SZ) atropine sulfate eye drops were approved for marketing on March 5, 2024.
Okanvision Bio-B (01477.HK) held a board meeting on March 21 to approve annual results
Glonghui March 7 | Okanvision Bio-B (01477.HK) announced that the company will hold a board meeting on March 21, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider recommending payment of a final dividend (if any).
OCUMENSION-B: DATE OF BOARD MEETING
Private Equity Firms Among Ocumension Therapeutics' (HKG:1477) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop
Key Insights Significant control over Ocumension Therapeutics by private equity firms implies that the general public has more power to influence management and governance-related decisions A total
Okanvision Bio-B (01477.HK) spent HK$2.69,000 to buy back 483,500 shares on January 19
Gelonghui, January 19 | Okanvision Bio-B (01477.HK) announced that on January 19, it spent HK$2.69,000 to buy back 483,500 shares, at a price of HK$5.8-5.51 per share.
Okanvision Bio-B spent approximately HK$3.424,900 to buy back 578,000 shares on January 18
Okanvision Bio-B (01477) announced that on January 18, 2024, it spent approximately HK$3.424,900 to repurchase 578,000 shares at a repurchase price of HK$5.62-6.047 per share.
Okanvision Bio-B (01477) spent approximately HK$3.424,900 to buy back 578,000 shares on January 18
According to the Zhitong Finance App, Okanvision Bio-B (01477) announced that on January 18, 2024, it spent approximately HK$3.424,900 to repurchase 578,000 shares at a repurchase price of HK$5.62-6.047 per share.
No Data